Compare HTCR & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTCR | QUCY |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | Japan | Germany |
| Employees | N/A | 13 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 5.9M |
| IPO Year | 2022 | 2021 |
| Metric | HTCR | QUCY |
|---|---|---|
| Price | $3.30 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 218.6K | ★ 229.2K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | ★ 81.76% | N/A |
| EPS Growth | ★ 414.29 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $30,407,229.00 | N/A |
| Revenue This Year | N/A | $74.34 |
| Revenue Next Year | $3.52 | $171.48 |
| P/E Ratio | $14.45 | ★ N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.15 | $0.40 |
| 52 Week High | $3.97 | $0.74 |
| Indicator | HTCR | QUCY |
|---|---|---|
| Relative Strength Index (RSI) | 74.09 | 50.87 |
| Support Level | $0.42 | $0.42 |
| Resistance Level | $3.97 | N/A |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 82.19 | 99.95 |
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.